Our data in PPM1D-mutant patient-derived DMG cultures nominates therapeutic targets (i.e. MDM2) that reactivate TP53. In addition, interactions of glioma cells with the tumor microenvironment can be fully evaluated since IUE mouse models develop as de novo tumors in immune-competent mice. Here, MDM2 is linked to neoplasm.